MY ACCOUNT | NEWSLETTER |

Canine apocrine gland anal sac adenocarcinoma: a review


In this article, the study's authors review the clinical signs, diagnosis, staging, treatment, and prognosis of apocrine gland anal sac adenocarcinoma (AGASAC) in dogs. AGASAC is a relatively uncommon tumor in dogs and comprises approximately 17% of perianal malignancies. It is, however, one of the most common causes of paraneoplastic hypercalcemia.  

Clinical signs in affected dogs most commonly are associated with mechanical obstruction caused by the primary tumor or enlarged regional metastatic lymph nodes and the effects of paraneoplastic hypercalcemia when present. Surgical excision of the primary tumor and metastasectomy of the affected locoregional lymph nodes is the preferred initial treatment option for most dogs, although radiation therapy and adjuvant chemotherapy are commonly incorporated into multi-modality treatment plans.  

A significant role for the use of adjuvant chemotherapy has not been clearly demonstrated. Prolonged survival times are possible, especially for dogs with smaller primary tumors and for dogs that undergo further treatments for recurrent disease. 

Canine Apocrine Gland Anal Sac Adenocarcinoma: A Review.” Alec B Repasy, et al. Top Companion Anim Med. 2022 Jul 2;100682. doi: 10.1016/j.tcam.2022.100682. 

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Texas A&M study links cattle feed additive to heart damage in dogs

Like0
Dislike0

May 12, 2026 Inaugural Cat Camp Research Grants go to Four Feline-Focused Participants

Like0
Dislike0

Research • Veterinary Biosciences • Veterinary Preventive Medicine Study of influenza D in human cells, tissue h...

Like0
Dislike0

Undergrad researchers drive discovery in the College of Veterinary Medicine

Like0
Dislike1

Phibro Animal Health Corporation Launches Companywide Sustainable Solutions Platform; Introduces VERRATAIN™ Verified Sustainability Solutions Through Strategic VAXA Technologies Partnership

Like0
Dislike1

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top